Protalix-Pfizer Tag Team Against Genzyme: BioBuzz
New partnership for Gaucher's drug takes aim at Genzyme.
10:09AM 12/01/09
Genzyme's Termeer: Worst Biotech CEO of '09
Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.
12:31PM 11/17/09
Should You Buy It? Impax Labs (RealMoney.com $)
Impax's third-quarter earnings beat flew under the market radar.
11:45AM 11/05/09
Bulls Target Shire, Conoco: Options Recap
Bullish options traders bet on Shire and ConocoPhillips, according to OptionMonster.
10:03AM 09/24/09
Cell Therapeutics' Pixantrone: Priority Review or Not?
FDA review status of Cell Therapeutics' key cancer drug Pixantrone is unclear.
02:12PM 08/31/09
Greater than expected job losses in the private sector weigh on stocks despite an improving trend, but the indices closed off their lows for the day.
05:14PM 08/05/09
Here's what stood out in the market today.
05:55PM 08/03/09
Shire to Take on Genzyme With Gaucher Drug
Shire will seek U.S. regulatory approval for its Gaucher drug following the release of positive phase III study results.
09:46AM 08/03/09
Approaching a Breaking Point (RealMoney.com $)
The market may soon break out of its range, and the likely direction is down.
08:30AM 05/22/09
Cramer's 'Mad Money' Follow-Up: Emerson
It might go against common sense, said Jim Cramer, but Emerson's a buy.
05:54PM 04/09/09
Cramer's 'Mad Money' Recap: Where Investors Go Astray
Cramer discusses 10 common mistakes of investing.
08:45PM 04/08/09
'Mad Money Lightning Round': Quanta Services Is Solid
Cramer sees the stock going to $23.
07:43PM 04/08/09
What's on Lilly's Prescription Pad?
Eli Lilly's CEO didn't reveal which companies he's looking at, but let's take some educated guesses.
02:20PM 03/31/09
Shire Chairman Matthew Emmens will assume the role of CEO when Joshua Boger retires in May.
05:10PM 02/05/09



Connect with TheStreet